With Kite’s PDU­FA date loom­ing, fed­er­al court toss­es Juno’s CAR-T patent chal­lenge — for now

Juno Ther­a­peu­tics $JUNO was spoil­ing to bat­tle ri­val CAR-T de­vel­op­er Kite Phar­ma $KITE in court over claims that its lead ther­a­py had in­fringed on its patent. But to­day Juno says that the suit was thrown out af­ter the U.S. Dis­trict Court for the Dis­trict of Delaware de­ter­mined that it lacked ju­ris­dic­tion un­til af­ter an ap­proval oc­curs.

Ac­cord­ing to Juno, the court de­ter­mined that there was no ev­i­dence that an FDA ap­proval of Kite’s ther­a­py – axi­cab­ta­gene ciloleu­cel, or KTE-C19 – “is im­mi­nent or even cer­tain.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER